Ask AI
ProCE Banner Events

Share

Advances in Immunotherapy for Earlier Stages of Cancer: Guidance for Multidisciplinary Teams [Open Registration]

Register now for this interactive, case-based workshop series to hear about recent advances in the use of immunotherapy for patients with early stages of cancer. After the meeting, download the associated slideset for use in your clinic.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

This event has expired. No longer available for credits.

Credits Available

1.0

Who Should Attend

This program is intended for multidisciplinary teams consisting of medical oncologists, radiation oncologists, thoracic oncologists, pulmonologists, surgeons, nurses, pharmacists, and other community healthcare professionals involved in the neoadjuvant or adjuvant treatment of patients with early-stage cancer.

Time and location

Tuesday, October 03, 2023

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group AL
Mobile, Alabama

Agenda

  • Introduction
  • Rationale for the Use of Immunotherapy in Early Stages of Cancer
  • Review of Recent Approvals and Key Clinical Trial Data
  • Effective Strategies in Immuno-Oncology to Ensure Optimal Care of Patients
  • Final Thoughts and Audience Question and Answer Session

Location

Venue Name

CCO Simulcast | Host Group AL

Address

CCO Simulcast | Host Group AL
Mobile, Alabama

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging immuno-oncology therapies in earlier stages of cancer into clinical practice.

Target Audience
This program is intended for multidisciplinary teams consisting of medical oncologists, radiation oncologists, thoracic oncologists, pulmonologists, surgeons, nurses, pharmacists, and other community healthcare professionals involved in the neoadjuvant or adjuvant treatment of patients with early-stage cancer.

Learning Objectives:

  • Assess the biologic rationale for the use of immuno-oncology in earlier stages of cancer, considering the available clinical data, impact on tumor natural history, and immune-related implications. 
  • Evaluate clinical trial data and endpoints, including survival surrogates, on the use of immune checkpoint as neoadjuvant/adjuvant therapy to inform patients earlier stages of cancer on the potential long-term benefits of this therapeutic strategy
  • Identify patients with early-stage solid cancers who would be appropriate for treatment or clinical trial enrollment with immune checkpoint inhibitors in the neoadjuvant, adjuvant, or maintenance/consolidation setting based on recurrence risk, surgical considerations, biomarkers, risk–benefit considerations, as well as potential disparities (socio-economic, racial, and age) in care
  • Identify and manage common and serious immune-related adverse events associated with immuno-oncology agents in early stages of cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-073-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Merck Sharp & Dohme LLC.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.